Pentagon Wants Clinical Trial of Humira for Covid-19 Treatment

The Defense Department is interested in the use of the anti-inflammatory drug Humira to treat Covid-19 patients and wants to test its effectiveness.

It’s looking for companies that could perform a randomized Phase II clinical trial, according to a request for information the Army published on Wednesday. In a very small clinical trial, it said the drug reduced patients’ mortality rate from the virus by more than half.

“Collectively the evidence, along with variable administration routes, strongly supports the rationale for early intervention in COVID‐19 patients to prevent hospitalization and progression of severe disease,” the solicitation says.

Company responses are ...